title: Continuous itraconazole treatment for onychomycosis and dermatomycosis: an overview of safety.
abstract: Over the past 10 years, itraconazole has been used to treat more than 34 million patients worldwide. We present a review of the safety of various continuous itraconazole schedules used in the treatment of dermatomycosis and onychomycosis. Data from controlled clinical trials and extensive post-marketing surveillance show that itraconazole has an impressive safety profile at a dose of 50-200 mg/day for 1-4 weeks for dermatomycosis and 200 mg/day for 3 months for onychomycosis. In addition, itraconazole is safe to use in diabetic patients with dermatomycosis or onychomycosis. Short-term, intermittent itraconazole regimens, which may offer additional benefits in terms of safety and cost, have now been introduced.
authors.affiliation: Universitäts-Hautklinik, von Esmarch-Str. 56, 48149 Münster, Germany.
authors.forename: S K
authors.initials: SK
authors.lastname: Nolting
authors.forename: A
authors.initials: A
authors.lastname: Gupta
authors.forename: P D
authors.initials: PD
authors.lastname: Doncker
authors.forename: M L
authors.initials: ML
authors.lastname: Jacko
authors.forename: B L
authors.initials: BL
authors.lastname: Moskovitz
mesh_terms: D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003881:Dermatomycoses / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008111:Liver Function Tests; D012871:Skin Diseases / Q000139:chemically induced
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole